CLDX Celldex Therapeutics

Celldex to Participate in Upcoming November Investor Conferences

Celldex to Participate in Upcoming November Investor Conferences

HAMPTON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following investor conferences in November:

  • Guggenheim 4th Annual Immunology and Neurology Conference on Monday, November 14, 2022 at 2:10 p.m. ET
  • Jefferies London Healthcare Conference on Wednesday, November 16, 2022 at 4:45 a.m. ET / 9:45 a.m. GMT
  • Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022 at 4:45 p.m. ET

Webcasts of the presentations will be available on the of the section of the Celldex website. Replays will be available for 30 days following the events.

About Celldex Therapeutics, Inc.

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit .

Company Contact

Sarah Cavanaugh

Senior Vice President, Corporate Affairs & Administration

(508) 864-8337

Patrick Till

Meru Advisors

(484) 788-8560



EN
10/11/2022

Underlying

CLDXCelldex Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Celldex Therapeutics

 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Presents Data Demonstrating Profound Long Term Improvement in ...

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spont...

June 14, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phas...

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025 Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0)48% of patients (150 mg Q4W) report that CSU no longer impacts their quality of life (DLQI=0/1)KIT related tolerability events demonstrated to be reversible Enrollment to Phase 3 CSU trials ongoingCompany to host webcast today at 6:00 pm ET HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new dat...

June 12, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data...

Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress Company to host webcast on Thursday, June 12 at 6:00 pm ET HAMPTON, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that data from the Company’s Phase 2 study of barzolvolimab in chronic spontaneous urticaria will be presented at the EAACI Congress 2025 being held in Glasgow, Scotland. Abstracts will be available on the meeting website Thursday, June 12th at 6:01 pm ET/ Friday, June 13th at 12:01 am CEST. Celldex will host a webcast...

June 10, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Therapeutics Announces Election of Denice Torres to its Board ...

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company’s Board of Directors. "We are excited to welcome Denice to the Celldex Board of Directors," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex. "Denice’s extensive leadership experience across both the pharmaceutical and consumer healthcare sectors brings a deep operational and commercial perspective to our team. Her ...

June 6, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Reports First Quarter 2025 Financial Results and Provides Corp...

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update Strong execution and progress across pipeline with multiple key data read outs expected in 2025Late breaking oral presentation on Phase 2 CSU program at EAACI 2025 in JunePhase 3 barzolvolimab CSU studies enrollment ongoing; Phase 3 program in CIndU under developmentPhase 2 EOE study enrollment complete; ongoing enrollment in Phase 2 PN and AD studiesCelldex’s first bispecific for inflammatory diseases, CDX-622, Phase 1 study ongoing HAMPTON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc...

May 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch